Hershberg Robert
- SEC CIK
- 0001274139
In the past year, 3 open-market sale filings worth $1.61M and no purchases.
Current role at each company
- ATAI AtaiBeckley Inc.Directoras of Sep 11, 2026
- ADPT Adaptive Biotechnologies CorpDirectoras of Aug 20, 2026
- RXRX Recursion Pharmaceuticals, Inc.Directoras of Jun 22, 2026
- HLVX HilleVax, Inc.President and CEOas of Sep 17, 2025
- FATE Fate Therapeutics IncDirectoras of Jun 7, 2023
Show 2 more companies
- SPRY ARS Pharmaceuticals, Inc.Directoras of Jun 13, 2022
- NSTG NS Wind Down Co., Inc.Directoras of Apr 18, 2022
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $1.61M
- 3 filings
- Net
- −$1.61M
- Bought minus sold
- Companies
- 2
- With open-market trades
Trades
Every Form 4 that lists Hershberg Robert as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
ADPT Adaptive Biotechnologies Corp
Director3 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2025 (view filing) | Mar 12 | Same day | Hershberg RobertDirector | SSale | −53.0K | $7.59 | −$402.3K | −43.2%69.7K after | |
| Dec 12, 2025 (view filing) | Dec 10 | 2 days | Hershberg RobertDirector | SSale | −23.0K | $16.00 | −$367.5K | −33.0%46.7K after | |
| Aug 20, 2026 (view filing)5:55 PM ET | Aug 18 | 2 days | Hershberg RobertDirector | SSale | −30.7K | $24.40 | −$748.2K | −39.6%46.7K after | 2 lots |
ATAI AtaiBeckley Inc.
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 9, 2026 (view filing)5:30 PM ET | Jul 7 | 2 days | Hershberg RobertDirector | SSale | −100.0K | $4.96 | −$496.0K | −50.0%100.0K after | 10b5-1 |
HLVX HilleVax, Inc.
President and CEO2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 (view filing) | Feb 8 | 4 days | Hershberg RobertSee Remarks | SSale | −11.6K | $14.93 | −$173.1K | −1.2%953.8K after | |
| Feb 12, 2025 (view filing) | Feb 4-11 | 8 daysLate | Hershberg RobertSee Remarks | SSale | −26.5K | $1.83 | −$48.6K | −2.4%1.10M after | 2 lots |
FATE Fate Therapeutics Inc
Director1 trade
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 6, 2022 (view filing) | Jun 3 | 3 days | Hershberg RobertDirector | SSale | −672 | $22.75 | −$15.3K | −25.1%2.01K after |